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Blood Lipids and the Incidence of Atrial Fibrillation: The Multi-Ethnic
Study of Atherosclerosis and the Framingham Heart Study
Alvaro Alonso, MD, PhD; Xiaoyan Yin, PhD; Nicholas S. Roetker, BA; Jared W. Magnani, MD, MSc; Richard A. Kronmal, PhD;
Patrick T. Ellinor, MD, PhD; Lin Y. Chen, MD, MS; Steven A. Lubitz, MD, MPH; Robyn L. McClelland, PhD;
David D. McManus, MD, MSc; Elsayed Z. Soliman, MD, MS, MSc; Rachel R. Huxley, DPhil; Saman Nazarian, MD, PhD;
Moyses Szklo, MD, PhD; Susan R. Heckbert, MD, PhD;* Emelia J. Benjamin, MD, MSc*
Background-—Dyslipidemia is a major contributor to the development of atherosclerosis and coronary disease. Its role in the
etiology of atrial ﬁbrillation (AF) is uncertain.
Methods and Results-—We studied 7142 men and women from the Multi-Ethnic Study of Atherosclerosis (MESA) and the
Framingham Heart Study who did not have prevalent AF at baseline and were not on lipid-lowering medications. Total cholesterol,
high-density lipoprotein and low-density lipoprotein cholesterol, and triglycerides were measured using standard procedures.
Incident AF during follow-up was identiﬁed from hospital discharge codes; review of medical charts; study electrocardiograms; and,
in MESA only, Medicare claims. Multivariable Cox proportional hazards models were used to estimate hazard ratios and 95%
conﬁdence intervals of AF by clinical categories of blood lipids in each cohort. Study-speciﬁc results were meta-analyzed using
inverse of variance weighting. During 9.6 years of mean follow-up, 480 AF cases were identiﬁed. In a combined analysis of
multivariable-adjusted results from both cohorts, high levels of high-density lipoprotein cholesterol were associated with lower AF
risk (hazard ratio 0.64, 95% CI 0.48 to 0.87 in those with levels ≥60 mg/dL versus <40 mg/dL), whereas high triglycerides were
associated with higher risk of AF (hazard ratio 1.60, 95% CI 1.25 to 2.05 in those with levels ≥200 mg/dL versus <150 mg/dL).
Total cholesterol and low-density lipoprotein cholesterol were not associated with the risk of AF.
Conclusion-—In these 2 community-based cohorts, high-density lipoprotein cholesterol and triglycerides but not low-density
lipoprotein cholesterol or total cholesterol were associated with the risk of AF, accounting for other cardiometabolic risk factors.
( J Am Heart Assoc. 2014;3:e001211 doi: 10.1161/JAHA.114.001211)
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D yslipidemia is a major contributor to the development ofatherosclerosis and coronary heart disease. High levels
of low-density lipoprotein cholesterol (LDLc), and low levels of
high-density lipoprotein cholesterol (HDLc) have been consis-
tently associated with increased risk of coronary heart
disease.1 In addition, lowering of LDLc and total cholesterol
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with statins reduces the risk of coronary events.2 The role of
dyslipidemia as a risk factor for other cardiac conditions,
including atrial ﬁbrillation (AF), is less clear. Prevalence and
severity of atherosclerosis have been associated with the risk
of AF,3 but the few published studies exploring the link
between blood lipids and AF have yielded inconsistent and
paradoxical results. In contrast with the association observed
with coronary heart disease, high levels of LDLc and total
cholesterol were unexpectedly associated with lower risk of
AF in some community-based studies.4–8 With the general aim
of clarifying the role of blood lipids as risk factors for AF, we
analyzed data from the Multi-Ethnic Study of Atherosclerosis
(MESA) and the Framingham Heart Study (FHS), 2 community-
based studies in the United States that have collected
extensive information on cardiovascular risk factors including
blood lipids.
Methods
Study Cohorts
MESA is a racially diverse, community-based, prospective
cohort study designed to investigate the prevalence, progres-
sion, and risk factors of subclinical cardiovascular disease
(CVD) in the general population. Details of the overall design,
recruitment, and methods have been published elsewhere.9
Brieﬂy, 6814 men and women aged 45 to 84 years and without
known CVD were recruited in 2000–2002 from 6 US commu-
nities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los
Angeles County, CA; New York City, NY; and Saint Paul, MN).
The FHS is a prospective, community-based investigation
of the epidemiology of CVD. The study began in 1948 with the
enrollment of the original cohort. In the early 1970s, offspring
and spouses of the original cohort were recruited into the
Framingham Offspring Study and examined every 4 to 8 years
afterward.10 In the present analysis, we included 3532
participants attending the sixth examination cycle of the
Framingham Offspring Study (1995–1998; age range: 30 to
87 years), considered baseline for this analysis.
For the primary analysis, we excluded participants with
prevalent AF at baseline, those taking lipid-lowering medica-
tions, and those with missing values for any relevant covariates
(Figure 1). Participants with prevalent myocardial infarction or
heart failure in the FHS were also excluded (by design, MESA
participants were free of clinical CVD at baseline). After
applying exclusion criteria, 4534 participants in MESA and
2608 in the FHS were eligible. The study was approved by
institutional review boards at participating institutions. All
participants provided written informed consent.
Measurement of Lipid Levels
In MESA and the FHS, fasting blood samples were collected at
baseline, processed, and stored at 70°C. Total cholesterol,
HDLc, and triglycerides were measured using standard
methods.11,12 LDLc was calculated using the Friedewald
equation (all values in mg/dL): LDLc=total choles-
terolHDLctriglycerides90.2.13
Ascertainment of Atrial Fibrillation
Incident cases of AF during follow-up in MESA were identiﬁed
through MESA event surveillance and, for participants
enrolled in fee-for-service Medicare, from inpatient Medicare
claims data. As part of standard event surveillance procedures
in the MESA cohort, all hospitalizations are identiﬁed every 9
to 12 months during follow-up calls to study participants or a
proxy. Discharge diagnostic and procedure codes from those
hospitalizations are abstracted. AF was considered to be
present if an International Classiﬁcation of Diseases, Ninth
Figure 1. Flowchart of study participants: MESA, 2000–2002, and the FHS, 1995–1998. AF indicates
atrial ﬁbrillation; CVD, cardiovascular disease; FHS, Framingham Heart Study; HF, heart failure; MESA, Multi-
Ethnic Study of Atherosclerosis; MI, myocardial infarction; NT-proBNP, N-terminal prohormone of B-type
natriuretic peptide.
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Revision, Clinical Modiﬁcation code 427.31 or 427.32 was
present in any position. AF hospitalizations associated with
open cardiac surgery were excluded. Similarly, in Medicare
claims, AF was deﬁned as the presence of an International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁca-
tion code 427.31 or 427.32 in any position in any inpatient
claim during 1999–2010. If the ﬁrst AF claim occurred before
the baseline MESA exam, the participant was considered to
have prevalent AF and thus was excluded from the analysis.
In the FHS, AF was diagnosed if AF or atrial ﬂutter were
present on an ECG obtained from a Framingham clinic visit,
outpatient clinical visit, inpatient hospitalization, or Holter
monitor. All potential AF cases were adjudicated by an FHS
cardiologist.14
Assessment of Other Covariates
In both MESA and the FHS, information on cardiovascular risk
factors and other variables was collected during the baseline
examination following standardized protocols. Education,
smoking history, alcohol intake, and use of medications were
assessed through questionnaires. Physical activity was
assessed by an activity questionnaire adapted from the
Cross-Cultural Activity Participation Study (in MESA)15 and by
asking how many times per week the participant engaged in
intense physical activity (in the FHS). Resting blood pressure,
height, and weight were measured with the participant in light
clothing. Body mass index was calculated as the weight in
kilograms divided by height in square meters. Fasting blood
glucose and high-sensitivity C-reactive protein were measured
using comparable methods in both cohorts.16,17 Diabetes was
deﬁned based on having fasting blood glucose >125 mg/dL or
a history of medical treatment for diabetes. B-type natriuretic
peptide (BNP) was measured in FHS participants using a high-
sensitivity immunoradiometric assay (Shionogi), and N-termi-
nal prohormone of BNP (NT-proBNP) was measured in MESA
using a commercially available immunoassay (Roche Diagnos-
tic Elecsys proBNP assay) on the Elecsys 2010 instrument.
Statistical Analysis
Separate analyses were conducted with MESA and FHS data.
We examined the association of baseline blood lipid levels
with AF incidence calculating hazard ratios (HRs) and 95% CIs
from Cox proportional hazard models. Initially, we conducted
analyses using established clinical cut points: <200, 200 to
239, and ≥240 mg/dL for total cholesterol; <100, 100 to
129, 130 to 159, and ≥160 mg/dL for LDLc; <40, 40 to 59,
and ≥60 mg/dL for HDLc; and <150, 150 to 199, and
≥200 mg/dL for triglycerides.18 In additional models, we
included lipid levels as continuous variables scaled to
approximately 1SD increments, using the same values in
both cohorts. Models were initially adjusted for age; sex; and,
in MESA only, race or ethnicity. In a second model, we
adjusted for other potential confounders, including study site
(in MESA), education, body mass index, height, smoking,
alcohol intake, systolic and diastolic blood pressure, use of
antihypertensive medications, diabetes, C-reactive protein,
and loge-transformed NT-proBNP (in MESA) or BNP (in the
FHS). Participants with NT-proBNP or BNP levels below the
limit of detection were assigned the detection limit value
(n=289 in MESA, n=844 in the FHS). Finally, we ran a model
additionally adjusting for incident heart failure and myocardial
infarction as time-dependent covariates to determine whether
associations between blood lipids and AF incidence were
mediated by incident cardiac disease. Heart failure and
myocardial infarction events diagnosed on the same date as
AF cases were considered interim events for this analysis. The
proportional hazards assumption was assessed including
interaction terms between time and the independent variable
of interest and exploring log(-log) survival curves. No viola-
tions of the assumption were found. We examined interac-
tions between lipid levels and age, sex, race or ethnicity, and
obesity status including multiplicative terms in the Cox
models. Results from MESA and the FHS were combined
using ﬁxed-effects meta-analysis. Between-study heterogene-
ity was assessed using Cochran’s Q statistic and I2.19,20
Four additional analyses were conducted in the MESA
cohort only. First, we evaluated the impact of excluding
participants taking lipid-lowering medications in the primary
analysis. Speciﬁcally, for participants taking lipid-lowering
medications at baseline and without missing covariates
(n=860), we imputed the underlying untreated levels of total
cholesterol based on their observed values under treatment
and the observed changes in lipid levels associated with
treatment among other MESA cohort members who started
lipid-lowering therapy during cohort follow-up, as described
previously.21 In a second sensitivity analysis in MESA, we
determined the impact of AF case-ascertainment method on
the estimates of association, repeating the analysis and
excluding events identiﬁed only through Medicare claims.
Because Medicare claims were available only from partici-
pants aged 65 years or older enrolled in fee-for-service
Medicare, differential outcome misclassiﬁcation could occur if
lipid levels were associated with Medicare enrollment. Third,
we conducted an analysis additionally adjusting for health
insurance status (no insurance, private insurance, Medicare,
Medicaid, military or US Department of Veterans Affairs
sponsored, other type of health insurance) and annual income
(<$20 000, $20 000 to <$50 000, $50 000 or more) to
account for the impact of access to health care in the
ascertainment of AF. Finally, because NT-proBNP was missing
for a sizable proportion of MESA participants, we used
multiple imputation to create 30 data sets including the
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following variables: age, sex, race or ethnicity, study site,
education, height, body mass index, smoking status, alcohol
drinking, physical activity, systolic and diastolic blood
pressure, use of antihypertensive medication, diabetes, C-
reactive protein, end point status, and the Nelson–Aalen
estimate of the baseline cumulative hazard, as recommended
elsewhere.22
Results
In MESA, over a mean follow-up of 8.2 years (median 8.7
years), 221 incident AF cases were identiﬁed among 4534
eligible participants, whereas in the FHS, 259 incident AF
cases occurred in 2608 participants during a mean follow-up
of 11.9 years (median 12.7 years). Table 1 provides baseline
characteristics by cohort. With the exception of the racial and
ethnic distribution, the 2 cohorts had similar cardiovascular
risk proﬁles.
The associations between blood lipid levels and AF
incidence are presented in Table 2. Because no evidence of
between-cohort heterogeneity existed, combined results are
presented. Cohort-speciﬁc results are provided in supplemen-
tary Table S1. In age, sex, and race-adjusted models, total
cholesterol was not associated with AF risk, whereas high
levels of HDLc and LDLc and low levels of triglycerides were
associated with lower risk of AF. After adjustment for
potential confounders, total cholesterol and LDLc were not
associated with lower risk of AF. In contrast, higher HDLc
remained associated with lower AF risk (HR 0.64, 95% CI 0.48
to 0.87 comparing HDLc levels ≥60 mg/dL and <40 mg/dL),
whereas risk of AF was elevated in those with higher
triglycerides (HR 1.60, 95% CI 1.25 to 2.05 comparing
triglyceride levels ≥200 mg/dL and <150 mg/dL) (Table 2,
Model 2). The associations of HDLc and triglycerides with AF
were slightly attenuated after adjustment for incident heart
failure and myocardial infarction as time-dependent
Table 1. Baseline Characteristics by Cohort: MESA, 2000–2002, and the FHS, 1995–1998
MESA FHS
n 4534 2608
Age, y 62 (10) 58 (10)
Female, % 52 56
Race or ethnicity, %
White 39 100
Black 24 0
Hispanic 24 0
Chinese American 14 0
Completed high school, % 82 95
Body mass index, kg/m2 28 (6) 28 (5)
Height, cm 167 (10) 168 (9)
Current smoker, % 13 15
Current alcohol drinker, % 56 62
Systolic BP, mm Hg 126 (21) 127 (18)
Diastolic BP, mm Hg 72 (10) 75 (9)
Hypertension medications, % 32 23
Diabetes, % 11 8
C-reactive protein, mg/L 3.8 (5.9) 4.4 (10.0)
NT-proBNP, pg/mL 99 (200) —
BNP, pg/mL — 14 (18)
Total cholesterol, mg/dL 196 (35) 207 (37)
HDLc, mg/dL 51 (15) 53 (16)
LDLc, mg/dL 120 (31) 129 (34)
Triglycerides, mg/dL 126 (66) 126 (65)
Values correspond to mean (SD) or percentage. BNP indicates B-type natriuretic peptide; BP, blood pressure; FHS, Framingham Heart Study; HDLc, high-density lipoprotein cholesterol;
LDLc, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; NT-proBNP, N-terminal prohormone of BNP.
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covariates (Table 2, Model 3). Similar associations were
observed using blood lipids as continuous instead of
categorical variables (Figure 2) and when only MESA white
participants were combined with FHS participants (Table S2).
Cohort-speciﬁc Kaplan–Meier survival curves are presented in
Figure 3 (HDLc, triglycerides) and Figure S1 (total cholesterol,
LDLc). Age, sex, race or ethnicity, and obesity status did not
signiﬁcantly modify the association of lipid levels with AF
incidence (Table 3; Tables S2 to S5).
In a sensitivity analysis in the MESA cohort, we excluded
54 AF events identiﬁed from Medicare claims only to avoid
differential outcome misclassiﬁcation. Results did not appre-
ciably change (Table S6). In addition, we conducted an
analysis including participants using lipid-lowering medica-
tions at baseline, implementing multiple imputation to adjust
their total cholesterol levels based on medication type and
dosage. This analysis included 5394 eligible participants and
272 AF events. The multivariable-adjusted HR of AF associ-
ated with a 1SD difference in total cholesterol was 1.06 (95%
CI 0.92 to 1.21), very similar to the model not including lipid-
lowering medication users (Table 4). Finally, associations
remained unchanged after additional adjustment for health
Table 2. Hazard Ratios and 95% CIs of AF by Categories of Blood Lipids
Total Cholesterol, mg/dL <200 200 to 239 ≥240
AF events, no. 240 172 68
Person-years 34 004 23 980 9410
Incidence rate* 7.1 7.2 7.2
Model 1† 1 (Ref) 0.98 (0.81 to 1.20) 0.94 (0.71 to 1.24)
Model 2‡ 1 (Ref) 1.14 (0.93 to 1.40) 1.20 (0.90 to 1.60)
Model 3§ 1 (Ref) 1.13 (0.92 to 1.39) 1.23 (0.92 to 1.64)
HDLc, mg/dL <40 40 to 59 ≥60
AF events, no. 139 237 104
Person-years 14 261 34 439 18 693
Incidence rate* 9.7 6.9 5.6
Model 1† 1 (Ref) 0.75 (0.60 to 0.93) 0.60 (0.45 to 0.79)
Model 2‡ 1 (Ref) 0.76 (0.59 to 0.98) 0.64 (0.48 to 0.87)
Model 3§ 1 (Ref) 0.80 (0.64 to 1.00) 0.66 (0.50 to 0.91)
LDLc, mg/dL <100 100 to 129 130 to 159 ≥160
AF events, no. 109 185 125 61
Person-years 15 221 24 681 18 504 8987
Incidence rate* 7.2 7.5 6.8 6.8
Model 1† 1 (Ref) 0.93 (0.74 to 1.18) 0.83 (0.64 to 1.07) 0.82 (0.59 to 1.13)
Model 2‡ 1 (Ref) 0.95 (0.75 to 1.20) 0.96 (0.73 to 1.25) 1.03 (0.74 to 1.43)
Model 3§ 1 (Ref) 0.98 (0.77 to 1.25) 0.95 (0.73 to 1.24) 1.06 (0.76 to 1.47)
Triglycerides, mg/dL <150 150 to 199 ≥200
AF events, n 316 76 88
Person-years 48 361 10 013 9019
Incidence rate* 6.5 7.6 9.8
Model 1† 1 (Ref) 1.11 (0.86, 1.42) 1.56 (1.23, 1.99)
Model 2‡ 1 (Ref) 1.10 (0.86, 1.43) 1.60 (1.25, 2.05)
Model 3§ 1 (Ref) 1.05 (0.81, 1.36) 1.54 (1.20, 1.97)
Combined results from MESA, 2000–2010, and the FHS, 1995–2010. AF indicates atrial ﬁbrillation; BNP, B-type natriuretic peptide; FHS, Framingham Heart Study; HDLc, high-density
lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol MESA, Multi-Ethnic Study of Atherosclerosis; NT-proBNP, N-terminal prohormone of BNP; Ref, reference.
*Per 1000 person-years.
†Model 1: Cox proportional hazards model adjusted for age, sex, and race or ethnicity (only in MESA).
‡Model 2: As Model 1, additionally adjusted for study site (only in MESA), education, height, body mass index, smoking status, alcohol drinking, physical activity, systolic and diastolic blood
pressure, use of antihypertensive medication, diabetes, C-reactive protein, and loge(NT-proBNP) (in MESA) or loge(BNP) (in the FHS).
§Model 3: As Model 2, additionally adjusted for incident myocardial infarction and incident heart failure as time-dependent covariates.
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insurance status and income at baseline (Table S7) or after
imputing loge(NT-proBNP values) using multiple imputation
(Table S8).
Discussion
In 2 large community-based cohorts, high triglycerides and
low HDLc were associated with a higher risk of AF after
accounting for relevant clinical risk factors and biomarkers. In
contrast to previously published studies, LDLc and total
cholesterol were not associated with AF incidence. Results
were similar in both MESA and FHS data and robust in several
sensitivity analyses. The observed associations were consis-
tent across age, sex, and race and ethnicity groups.
The association between blood lipids and AF risk has been
studied in several previous publications, which have offered
inconsistent results. Similar to our observations, a post hoc
analysis of the Antihypertensive and Lipid Lowering Treatment
to Prevent Heart Attack (ALLHAT) trial found that lower levels
of baseline HDLc were associated with an increased risk of
AF.23 Associations with total cholesterol, LDLc, or triglyce-
rides were not reported. In contrast, a previous publication
from the ARIC study found high LDLc and total cholesterol to
be associated with a lower risk of AF, whereas HDLc and
triglycerides were not related to AF risk.5 In 2 Japanese
cohorts, high total cholesterol, HDLc, and LDLc were asso-
ciated with lower AF risk, but triglycerides were not associ-
ated with AF.4,7 Similar inverse association between LDLc and
AF risk was recently reported in the Women’s Health Study.8
The Cardiovascular Health Study also reported lower risk of
AF among participants with higher total cholesterol.6 Lack of
adjustment for important confounders may partly explain
inconsistencies between studies. In the present analysis, high
LDLc was associated with lower risk of AF in minimally
adjusted models but not after multivariable adjustment.
Adjustment for levels of natriuretic peptides (NT-proBNP or
Figure 2. Association of blood lipids with AF. Cohort-speciﬁc and combined HRs and 95% CIs associated
with a 1SD increment in blood lipids (total cholesterol: 35 mg/dL; HDLc: 15 mg/dL; LDLc: 35 mg/dL;
triglycerides: 65 mg/dL). P values are from heterogeneity tests. Cohort-speciﬁc estimates are combined
using ﬁxed-effects meta-analysis. Results from Cox proportional hazards models adjusted for age, sex, race
or ethnicity (only in MESA), study site (only in MESA), education, height, body mass index, smoking status,
alcohol drinking, physical activity, systolic and diastolic blood pressure, use of antihypertensive medication,
diabetes, C-reactive protein, and loge(N-terminal prohormone of B-type natriuretic peptide) (in MESA) or
loge(B-type natriuretic peptide) (in the FHS). FHS indicates Framingham Heart Study; HDLc, high-density
lipoprotein cholesterol; HR, hazard ratio; LDLc, low-density lipoprotein cholesterol; MESA, Multi-Ethnic
Study of Atherosclerosis.
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Table 3. Hazard Ratios and 95% CIs of AF Per 1SD* Increment in Blood Lipids by Sex: MESA, 2000–2010, and the FHS,
1995–2010
MESA FHS
Women Men P for Interaction Women Men P for Interaction
AF events, no. 81 140 119 140
Person-years 19 007 17 389 17 587 13 411
Total cholesterol† 1.09 (0.86 to 1.39) 1.15 (0.96 to 1.38) 0.42 0.99 (0.83 to 1.19) 0.97 (0.81 to 1.16) 0.43
HDLc† 0.81 (0.63 to 1.04) 0.88 (0.71 to 1.10) 0.69 0.95 (0.79 to 1.16) 0.93 (0.75 to 1.15) 0.69
LDLc† 1.24 (0.96 to 1.60) 1.11 (0.91 to 1.36) 0.94 0.94 (0.78 to 1.15) 0.93 (0.88 to 1.23) 0.56
Triglycerides† 1.00 (0.77 to 1.29) 1.23 (1.05 to 1.44) 0.17 1.20 (0.99 to 1.45) 1.11 (0.95 to 1.31) 0.45
AF indicates atrial ﬁbrillation; FHS, Framingham Heart Study; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of
Atherosclerosis.
*SD values: total cholesterol: 35 mg/dL; HDLc: 15 mg/dL; LDLc: 35 mg/dL; triglycerides: 65 mg/dL.
†Cox proportional hazards model adjusted for age, race or ethnicity (only in MESA), study site (only in MESA), education, height, body mass index, smoking status, alcohol drinking, physical
activity, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, and loge(N-terminal prohormone of B-type natriuretic peptide) (in MESA) or
loge(B-type natriuretic peptide) (in the FHS).
A B
C D
Figure 3. Kaplan–Meier curves presenting AF-free survival probabilities by categories of HDLc and
triglycerides in the MESA and FHS studies. A, HDLc in MESA. B, HDLc in FHS. C, triglycerides in MESA. D,
triglycerides in FHS. AF indicates atrial ﬁbrillation; FHS, Framingham Heart Study; HDLc, high-density
lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis.
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BNP) may be particularly important because an inverse
association between LDLc levels and NT-proBNP has
been described previously,24 and natriuretic peptides are
strong predictors of AF risk.25–27 Consequently, these
biomarkers might have confounded associations in the
previous studies. Other reasons for inconsistencies between
studies could be differences in the age distribution and racial
composition of the populations; prevalence of effect modiﬁers
and confounders, including obesity and other cardiometabolic
risk factors; AF ascertainment methods; and length of
follow-up.
The observed inverse association between HDLc and AF
risk observed in the MESA and FHS cohorts may be explained
by different mechanisms. High HDLc may reduce risk of AF
indirectly through the prevention of coronary heart disease
and heart failure,1,28 which are established risk factors for
AF.29 In our analyses, we observed a small attenuation of the
association between HDLc and AF after adjustment for
interim cardiovascular events, partly supporting this hypoth-
esis. Besides, HDLc has anti-inﬂammatory and antioxidant
properties,30 potentially inhibiting 2 pathophysiological path-
ways in AF.31,32 Even though we adjusted for numerous
potential confounders, residual confounding by lifestyles such
as physical activity, which is associated with higher HDLc and
possibly lower AF risk, could also explain the observed
results. The association of higher triglycerides with an
increased risk of AF may also be explained by increased risk
of overall CVD. As we observed for HDLc, the association of
triglycerides with AF incidence was partly attenuated after
adjustment for incident CVD. In addition, higher triglycerides
are a component of the metabolic syndrome, which has been
associated with the incidence of AF in community-based
cohorts.33,34 Finally, both high triglycerides and low HDLc are
associated with the presence of microvascular disease,35
although the role played by microvascular disease in AF
pathogenesis is not known.
For the present analysis, we excluded participants using
lipid-lowering medications to avoid the potential confounding
effect that these drugs, particularly statins, could have. In
small clinical trials, statins have been associated with reduced
risk of AF, although large trials have failed to support this
effect.36 Exclusion of lipid-lowering medication users, how-
ever, could have eliminated those with the highest underlying
levels of LDLc and total cholesterol, obscuring a potential
association with AF incidence. Nonetheless, in a sensitivity
analysis in the MESA cohort, we showed that excluding users
of lipid-lowering medication at baseline did not have a
meaningful impact on the association of total cholesterol with
AF incidence.
Our results add to the growing literature on blood lipids
and AF. This literature, however, is inconsistent, and the exact
role of blood lipids in the development of AF, if any, remains
to be determined. Future studies using Mendelian randomi-
zation (ie, using gene variants known to affect blood lipid
levels as an instrumental variable) may shed new light on the
causal relationships between blood lipids and AF, as they have
done for coronary heart disease.37 Moreover, whether lipid-
lowering drugs could be used for the primary prevention of AF
is uncertain.38
Some limitations of our study include the between-cohort
heterogeneity in AF event ascertainment and the measure-
ment of some covariates (eg, natriuretic peptides) and our
inability to identify participants with asymptomatic paroxys-
mal AF. In addition, most AF cases in the MESA cohort were
identiﬁed through hospital discharge codes. Consequently,
differential bias with regard to the outcome ascertainment
may have occurred if participants who were more likely to be
hospitalized for dyslipidemia-related conditions (eg, coronary
Table 4. Hazard Ratios (95% CIs) of Atrial Fibrillation by Total Cholesterol Categories, Including Primary Study Sample and Imputed
Cholesterol for 860 Participants Using Lipid-Lowering Medication at Baseline and Without Missing Covariates: Multi-Ethnic Study of
Atherosclerosis, 2000–2010
Total Cholesterol Categories, mg/dL Continuous
<200 200 to 239 ≥240 1SD Difference* P Value
AF events, no. 169 81 22 272
Person-years 25 567 13 728 4049 43 344
Incidence rate† 6.6 5.9 5.4 6.3
Model 1‡ 1 (Ref.) 1.01 (0.76, 1.34) 0.92 (0.62, 1.38) 0.97 (0.85, 1.10) 0.60
Model 2§ 1 (Ref.) 1.16 (0.86, 1.56) 1.15 (0.76, 1.73) 1.06 (0.92, 1.21) 0.44
AF indicates atrial ﬁbrillation.
*1SD for total cholesterol: 35 mg/dL.
†Per 1000 person-years.
‡Model 1: Cox proportional hazards model adjusted for age, sex, and race or ethnicity.
§Model 2: Cox proportional hazards model adjusted for age, sex, race or ethnicity, study site, education, height, body mass index, smoking status, alcohol drinking, physical activity,
systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, and loge(N-terminal prohormone of B-type natriuretic peptide).
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heart disease) were also more likely to be diagnosed with AF.
Nonetheless, the consistent results observed in both cohorts,
the presence of associations after adjustment for incident
CVD during the follow-up, and the robustness of our results
with additional adjustment for health insurance status and
extensive measures of socioeconomic status suggest that the
impact of differences and shortcomings in end point ascer-
tainment was probably limited. Despite the extensive adjust-
ment for risk factors and biomarkers of AF, residual
confounding may have affected the results. Finally, exclusion
of participants due to missing data may limit the generaliz-
ability of our ﬁndings and potentially bias the results.
Nonetheless, this study has major strengths, including the
combination of 2 different cohorts; use of a racially diverse
sample; the detailed assessment of cardiovascular risk
factors; and, in the FHS, the use of physician-adjudicated
AF events.
In conclusion, we found in 2 distinct and well-characterized
community-based cohorts that lower blood levels of HDLc and
higher levels of triglycerides were associated with an
increased risk of AF. No associations were observed between
total cholesterol or LDLc and AF risk. Future research should
address the clinical signiﬁcance of these associations, explore
underlying mechanisms, and assess the impact of modiﬁca-
tion of lipid levels in the development of AF.
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SUPPLEMENTAL MATERIAL 
Table S1. Hazard ratios (HR) and 95% confidence intervals (CI) of atrial fibrillation by categories of blood lipids, cohort-specific results. MESA, 
2000-2010, and FHS, 1995-2010 
 MESA FHS 
 Total cholesterol (mg/dL) 
 <200 200-239 ≥240  <200 200-239 ≥240  
AF events, n 127 74 20  113 98 48  
Person-years 20524 12174 3698  13480 11806 5712  
Model 1† 1 (Ref.) 1.10 (0.82, 1.48) 1.00 (0.62, 1.61)  1 (Ref.) 0.89 (0.68, 1.17) 0.91 (0.65, 1.29)   
Model 2‡ 1 (Ref.) 1.37 (1.01, 1.85) 1.28 (0.78, 2.08)  1 (Ref.) 0.98 (0.75, 1.30) 1.16 (0.82, 1.66)  
Model 3 1 (Ref.) 1.31 (0.96, 1.78) 1.32 (0.81, 2.17)  1 (Ref.) 1.00 (0.75, 1.32) 1.18 (0.83, 1.69)  
 HDLc (mg/dL) 
 <40 40-59 ≥60   <40 40-59 ≥60   
AF events, n 62 112 47  77 125 57  
Person-years 7776 19657 8963  6485 14782 9730  
Model 1 1 (Ref.) 0.74 (0.54, 1.02) 0.67 (0.44, 1.01)  1 (Ref.) 0.75 (0.56, 1.01) 0.55 (0.38, 0.81)  
Model 2 1 (Ref.) 0.75 (0.54, 1.04) 0.60 (0.39, 0.93)  1 (Ref.) 0.78 (0.53, 1.14) 0.68 (0.45, 1.01)  
Model 3 1 (Ref.) 0.80 (0.57, 1.11) 0.67 (0.43, 1.05)  1 (Ref.) 0.80 (0.59, 1.08) 0.68 (0.45, 1.02)  
 LDLc (mg/dL) 
 <100 100-129 130-159 ≥160 <100 100-129 130-159 ≥160 
AF events, n 58 92 50 21 51 93 75 40 
Person-years 9250 14251 9208 3687 5971 10430 9296 5300 
Model 1 1 (Ref.) 1.01 (0.72, 1.40) 0.92 (0.63, 1.34) 1.02 (0.62, 1.69) 1 (Ref.) 0.86 (0.61, 1.21) 0.75 (0.52, 1.06) 0.70 (0.46, 1.06) 
Model 2 1 (Ref.) 1.07 (0.77, 1.50) 1.21 (0.82, 1.79) 1.39 (0.83, 2.33) 1 (Ref.) 0.83 (0.59, 1.17) 0.78 (0.54, 1.12) 0.84 (0.55, 1.28) 
Model 3 1 (Ref.) 1.15 (0.82, 1.62) 1.20 (0.81, 1.78) 1.47 (0.87, 2.47) 1 (Ref.) 0.83 (0.59, 1.18) 0.78 (0.55, 1.13) 0.85 (0.56, 1.31) 
 Triglycerides (mg/dL) 
 <150 150-199 ≥200  <150 150-199 ≥200  
AF events, n 149 38 34  167 38 54  
Person-years 26068 5421 4907  22293 4592 4112  
Model 1 1 (Ref.) 1.28 (0.89, 1.83) 1.43 (0.98, 2.08)  1 (Ref.) 0.96 (0.67, 1.36) 1.66 (1.22, 2.26)  
Model 2 1 (Ref.) 1.33 (0.92, 1.91) 1.58 (1.06, 2.34)  1 (Ref.) 0.92 (0.64, 1.32) 1.61 (1.17, 2.22)  
Model 3 1 (Ref.) 1.17 (0.80, 1.70) 1.46 (0.98, 2.18)  1 (Ref.) 0.95 (0.66, 1.36) 1.59 (1.16, 2.19)  
Model 1: Cox proportional hazards model adjusted for age, sex, and race/ethnicity (only in MESA) 
2 
 
Model 2: As Model 1, additionally adjusted for study site (only in MESA), education, height, body mass index, smoking status, alcohol drinking, 
physical activity, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, and log(NT-proBNP) 
(MESA) or log(BNP) (FHS). 
Model 3: As Model 2, additionally adjusted for incident myocardial infarction and incident heart failure as time-dependent covariates 
 
  
3 
 
Table S2. Hazard ratios and 95% confidence intervals of atrial fibrillation per 1-standard deviation increment in blood lipids (total cholesterol: 35 
mg/dL, HDLc: 15 mg/dL, LDLc: 35 mg/dL, triglycerides: 65 mg/dL) by race/ethnicity, MESA 2000-2010 
 MESA Combined MESA 
whites + FHS 
 White Black Hispanic Chinese-American P for 
interaction 
 
AF events, n 125  43 41 12   
Person-years 14251 8739 8319 5088   
Total cholesterol       
HR (95%CI) a 0.99 (0.81, 1.20) 1.21 (0.88, 1.68) 1.19 (0.89, 1.59) 1.33 (0.65, 2.70) 0.73 0.99 (0.89, 1.10) 
HDLc       
HR (95%CI) a 0.84 (0.68, 1.04) 0.82 (0.58, 1.16) 0.79 (0.49, 1.27) 0.79 (0.34, 1.80) 0.74 0.90 (0.80, 1.01) 
LDLc       
HR (95%CI) a 1.05 (0.85, 1.31) 1.21 (0.85, 1.71) 1.19 (0.86, 1.65) 1.39 (0.62, 3.15) 0.88 0.98 (0.87, 1.10) 
Triglycerides       
HR (95%CI) a 1.04 (0.86, 1.26) 1.43 (1.03, 1.98) 1.23 (0.92, 1.63) 1.23 (0.67, 2.28) 0.27 1.12 (1.01, 1.24) 
a Cox proportional hazards model adjusted for age, sex, education, height, body mass index, smoking status, alcohol drinking, physical activity, 
systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, and log(NT-proBNP) 
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Table S3. Hazard ratios and 95% confidence intervals of atrial fibrillation by categories of HDLc by sex, MESA 2000-2010 and FHS 1995-2010. 
 MESA   FHS   
Women <40 40-59 ≥60  <40 40-59 ≥60  
AF events, n 9 43 29 15 60 44 
Person-years 1779 10133 7094 1506 7899 8181 
HR (95%CI) a 1 (ref.) 0.74 (0.34, 1.60) 0.54 (0.23, 1.23) 1 (ref.) 0.73 (0.40, 1.31) 0.62 (0.33, 1.17) 
Men       
AF events, n 53 69 18 62 65 13 
Person-years 5997 9523 1868 4977 580 1549 
HR (95%CI) a 1 (ref.) 0.76 (0.52, 1.12) 0.67 (0.37, 1.19) 1 (ref.) 0.85 (0.60, 1.22) 0.75 (0.40, 1.40) 
a Cox proportional hazards model adjusted for age, race/ethnicity (only in MESA), study site (only in MESA), education, height, body mass index, 
smoking status, alcohol drinking, physical activity, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive 
protein, and log(NT-proBNP) (in MESA) or log(BNP) in FHS. 
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Table S4. Hazard ratios and 95% confidence intervals of atrial fibrillation per 1-standard deviation increment in blood lipids (total cholesterol: 35 
mg/dL, HDLc: 15 mg/dL, LDLc: 35 mg/dL, triglycerides: 65 mg/dL) by age, MESA 2000-2010 and FHS 1995-2010.  
 MESA FHS 
 <65 ≥65 P for 
interaction 
<65 ≥65 P for 
interaction 
AF events, n 41 180  124 135  
Person-years 22110 14286  23897 7100  
Total cholesterol       
HR (95%CI) a 1.23 (0.95, 1.60) 1.08 (0.92, 1.27) 0.31 1.01 (0.83, 1.21) 0.95 (0.80, 1.14) 0.30 
HDLc       
HR (95%CI) a, b 1.12 (0.79, 1.60) 0.80 (0.66, 0.95) 0.04 1.03 (0.83, 1.27) 0.89 (0.72, 1.09) 0.48 
LDLc       
HR (95%CI) a 1.18 (0.89, 1.58) 1.14 (0.95, 1.35) 0.81 0.92 (0.75, 1.12) 0.95 (0.78, 1.15) 0.35 
Triglycerides       
HR (95%CI) a 1.16 (0.85, 1.60) 1.14 (0.99, 1.32) 0.85 1.17 (1.00, 1.38) 1.11 (0.92, 1.33) 0.22 
a Cox proportional hazards model adjusted for sex, race/ethnicity (only in MESA), study site (only in MESA), education, height, body mass index, 
smoking status, alcohol drinking, physical activity, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive 
protein, and log(NT-proBNP) (in MESA) or log(BNP) in FHS. 
b Combined results from MESA and FHS were 1.05 (95%CI 0.88, 1.26) for those <65 years old and 0.84 (95%CI 0.73, 0.96) for those 65 and older 
(p for interaction = 0.06) 
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Table S5. Hazard ratios and 95% confidence intervals of atrial fibrillation per 1-standard deviation increment in blood lipids (total cholesterol: 35 
mg/dL, HDLc: 15 mg/dL, LDLc: 35 mg/dL, triglycerides: 65 mg/dL) by obesity status, MESA 2000-2010 and FHS 1995-2010.  
 MESA FHS 
 Non-obese (BMI<30) Obese (BMI≥30) P for 
interaction 
Non-obese (BMI<30) Obese (BMI≥30) P for 
interaction 
AF events, n 151 70  171 88  
Person-years 25415 10981  23073 7925  
Total cholesterol       
HR (95%CI) a 1.17 (0.99, 1.38) 1.02 (0.78, 1.35) 0.89 1.00 (0.86, 1.16) 0.99 (0.77, 1.24) 0.91 
HDLc       
HR (95%CI) a 0.92 (0.77, 1.10) 0.61 (0.42, 0.87) 0.43 0.96 (0.81, 1.14) 0.87 (0.66, 1.16) 0.92 
LDLc       
HR (95%CI) a 1.17 (0.97, 1.40) 1.15 (0.85, 1.56) 0.93 0.99 (0.84, 1.17) 0.85 (0.65, 1.11) 0.84 
Triglycerides       
HR (95%CI) a 1.17 (0.99, 1.37) 1.15 (0.92, 1.45) 0.82 1.07 (0.91, 1.26) 1.33 (1.10, 1.60) 0.35 
a Cox proportional hazards model adjusted for age, sex, race/ethnicity (only in MESA), study site (only in MESA), education, height, smoking 
status, alcohol drinking, physical activity, systolic and diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, 
and log(NT-proBNP) (in MESA) or log(BNP) in FHS.
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Table S6. Hazard ratios (HR) and 95% confidence intervals (CI) of atrial fibrillation by categories of blood 
lipids excluding AF cases identified from Medicare claims. MESA, 2000-2010 
 Total cholesterol (mg/dL) 
 <200 200-239 ≥240  
AF events, n 99 54 14  
Person-years 19645 11689 3538  
Model 1† 1 (Ref.) 0.99 (0.70, 1.38) 0.84 (0.48, 1.49)  
Model 2‡ 1 (Ref.) 1.22 (0.86, 1.73) 1.16 (0.65, 2.08)  
 HDLc (mg/dL) 
 <40 40-59 ≥60   
AF events, n 53 81 33  
Person-years 7462 18796 8615  
Model 1 1 (Ref.) 0.62 (0.43, 0.89) 0.51 (0.31, 0.82)  
Model 2 1 (Ref.) 0.62 (0.43, 0.90) 0.45 (0.27, 0.75)  
 LDLc (mg/dL) 
 <100 100-129 130-159 ≥160 
AF events, n 49 63 40 15 
Person-years 8854 13662 8808 3548 
Model 1 1 (Ref.) 0.80 (0.55, 1.16) 0.85 (0.56, 1.29) 0.83 (0.46, 1.48) 
Model 2 1 (Ref.) 0.84 (0.57, 1.22) 1.14 (0.74, 1.75) 1.17 (0.65, 2.13) 
 Triglycerides (mg/dL) 
 <150 150-199 ≥200  
AF events, n 108 32 27  
Person-years 25009 5183 4681  
Model 1 1 (Ref.) 1.47 (0.99, 2.19) 1.51 (0.98, 2.31)  
Model 2 1 (Ref.) 1.53 (1.02, 2.28) 1.66 (1.06, 2.60)  
Model 1: Cox proportional hazards model adjusted for age, sex, and race/ethnicity 
Model 2: As Model 1, additionally adjusted for study site, education, height, body mass index, smoking 
status, alcohol drinking, physical activity, systolic and diastolic blood pressure, use of antihypertensive 
medication, diabetes, C-reactive protein, and log(NT-proBNP). 
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Table S7. Hazard ratios (HR) and 95% confidence intervals (CI) of atrial fibrillation by categories of blood 
lipids adjusting for health insurance status and income at baseline (N = 4408; 213 AF cases). MESA, 
2000-2010 
 Main model Additionally adjusted for health 
insurance status and income 
Total cholesterol 1.13 (0.98, 1.30) 1.13 (0.98, 1.31) 
HDLc 0.85 (0.71, 1.00) 0.82 (0.70, 0.97) 
LDLc 1.15 (0.99, 1.35) 1.16 (0.99, 1.36) 
Triglycerides 1.16 (1.02, 1.33) 1.17 (1.03, 1.34) 
Main model: Cox proportional hazards model adjusted for age, sex, race/ethnicity, study site, education, 
height, body mass index, smoking status, alcohol drinking, physical activity, systolic and diastolic blood 
pressure, use of antihypertensive medication, diabetes, C-reactive protein, and log(NT-proBNP). 
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Table S8. Hazard ratios (HR) and 95% confidence intervals (CI) of atrial fibrillation by categories of blood 
lipids with multiple imputation of log(NT-proBNP) concentrations. MESA, 2000-2010 
 Main model* Multiple imputation P-value** 
Total cholesterol 1.13 (0.98, 1.30) 1.08 (0.94, 1.23) 0.65 
HDLc 0.85 (0.71, 1.00) 0.88 (0.76, 1.03) 0.77 
LDLc 1.15 (0.99, 1.35) 1.09 (0.94, 1.26) 0.62 
Triglycerides 1.16 (1.02, 1.33) 1.08 (0.99, 1.19) 0.39 
*Main model: Cox proportional hazards model adjusted for age, sex, race/ethnicity, study site, 
education, height, body mass index, smoking status, alcohol drinking, physical activity, systolic and 
diastolic blood pressure, use of antihypertensive medication, diabetes, C-reactive protein, and log(NT-
proBNP). 
**P-value for the comparison of hazard ratios in the main analysis and in the analysis imputing log(NT-
proBNP) 
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Figure S1. Kaplan-Meier curves presenting AF-free survival probabilities by categories of total 
cholesterol and LDLc in the MESA and FHS studies. (a) Total cholesterol in MESA; (b) Total cholesterol in 
FHS; (c) LDLc in MESA; (d) LDLc in FHS 
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